RENAL LABS AND IMAGING: ESSENTIAL DIAGNOSTIC GUIDE
PA/Medical Student Handout
LEARNING OBJECTIVES
By the end of this module, you will be able to:
- Order appropriate labs based on clinical presentation (new patient vs. follow-up)
- Understand renal function assessment including eGFR, cystatin C, and creatinine limitations
- Interpret laboratory panels for specific disease states (CKD, HTN, GN)
- Select optimal imaging modality for common clinical scenarios
- Understand radiation exposure and contrast considerations
- Interpret imaging findings and recognize abnormalities
- Manage contrast-related risks in patients with reduced kidney function
SECTION 1: ESSENTIAL RENAL LABS
Lab Panels by Clinical Scenario
Panel 1: New Nephrotic Syndrome Patient
Order: RFP, CBC, PTH, Mg, Uric Acid, Monoclonal Screen (SPEP), UA with Micro, Albumin-to-Creatinine Ratio (ACR), Protein-to-Creatinine Ratio (PCR)
| Lab | Why Order? | What It Tells You |
|---|---|---|
| RFP | Renal function baseline | Creatinine, BUN, eGFR |
| CBC | Hematologic status | Anemia (hemolysis? bleeding?) |
| PTH | Mineral metabolism | Parathyroid status; renal osteodystrophy risk |
| Mg | Electrolyte screening | Hypomagnesemia common in proteinuria |
| Uric Acid | Gout risk; cell turnover | Can precipitate AKI during diuresis |
| SPEP | Screen for myeloma | Monoclonal protein? Light chain disease? |
| UA with Micro | Urine pathology | RBC casts? (GN) WBC casts? (infection) |
| ACR | Quantify proteinuria | Better than dipstick; albumin-specific |
| PCR | Total proteinuria | Includes non-albumin proteins |
Panel 2: Follow-Up CKD Patient (Stable)
Order: RFP, CBC, PTH, Mg, Uric Acid, ACR
Frequency: Q3-6 months if stable; Q1-2 months if declining
Panel 3: Hypertension Workup
Order: Cortisol (24-hour or late-night salivary), TSH, PTH, Plasma Free Metanephrines, Aldosterone-to-Renin Ratio
| Test | When to Order | What It Identifies |
|---|---|---|
| 24-hr Cortisol | Suspect Cushing’s | Cortisol excess (HTN + weight gain + striae) |
| TSH | Screen for thyroid | Hypothyroidism can cause HTN |
| PTH | Screen for hypercalcemia | Hyperparathyroidism (HTN + hypercalcemia) |
| Plasma Metanephrines | Suspect pheochromocytoma | Catecholamine excess (episodic HTN, sweating) |
| Aldo-Renin Ratio | Suspect primary aldosteronism | Hypokalemia + HTN (resistant to therapy) |
Panel 4: Glomerulonephritis Workup
Order: C3, C4, Hepatitis Panel, ANA, ANCA, Anti-GBM Antibody, Anti-dsDNA Antibody, Anti-PLA2R Antibody
| Antibody Test | Positive In | Clinical Significance |
|---|---|---|
| C3, C4 | Lupus, membranoproliferative GN | Complement consumption; disease activity |
| ANA | Lupus; must-have for SLE diagnosis | ANA-negative SLE exists but rare (<5%) |
| Anti-dsDNA | Lupus (specific); lupus nephritis | High titers = lupus activity |
| ANCA | ANCA-associated vasculitis | PR3-ANCA (granulomatosis) vs. MPO-ANCA (microscopic polyangiitis) |
| Anti-GBM | Anti-GBM disease (Goodpasture) | Pulmonary-renal syndrome; urgent need for plasmapheresis |
| Anti-PLA2R | Membranous nephropathy | 70-80% of cases; marker of disease remission |
| Hepatitis Panel | Screen before immunosuppression | Critical before starting azathioprine, mycophenolate |
SECTION 2: UNDERSTANDING RENAL FUNCTION
The eGFR Equation
CKDEPI 2021 Equation (currently recommended):
eGFR = 142 × (Serum Creatinine / λ)^α × (0.9938)^age × (0.7 if female)Where: - λ = 0.7 (females), 0.9 (males) - α = -0.241 (females), -0.302 (males)
Key Points: - eGFR predicts GFR-based kidney function (not tubular function) - eGFR becomes less accurate if: - Rapidly changing creatinine (AKI) - Extreme muscle mass (bodybuilders, amputees) - Liver cirrhosis - Pregnancy - Vegetarian diet (less creatinine production)
Cystatin C: Alternative Marker
Advantages of Cystatin C: - Produced at constant rate (independent of muscle mass) - Better in elderly, obese, or cachetic patients - Better predictor of cardiovascular events
Disadvantages: - More expensive than creatinine - Less standardized across labs - Still affected by inflammatory states, corticosteroid use
When to Use Cystatin C: - Borderline eGFR (45-60) for decision-making - Extreme body habitus - Elderly/frail patients with low muscle mass - When creatinine unreliable
SECTION 3: RENAL IMAGING MODALITIES
Quick Reference: Which Imaging for What?
| Clinical Scenario | BEST Modality | Why | Radiation | Contrast |
|---|---|---|---|---|
| Suspected stone | Non-contrast CT (gold standard) | 98% sensitivity; fast | Yes (low) | NO |
| Hydronephrosis? | Renal ultrasound | Radiation-free; real-time | No | NO |
| Renal mass | CT with contrast (multiphasic) | Enhancement characterization | Yes | YES (iodine) |
| RAS (high suspicion) | CT angiography | 94-100% sensitivity | Yes | YES (iodine) |
| RAS (screening) | Duplex ultrasound | Low sensitivity but no radiation | No | NO |
| Scarring from pyelonephritis | DMSA scintigraphy | Gold standard for cortical pathology | Yes (nuclear) | NO |
| Obstruction vs non-obstruction? | Diuretic renogram | Functional assessment; F+20 protocol | Yes (nuclear) | NO |
| Detailed mass characterization | MRI with contrast | Best soft tissue; NO radiation | NO | YES (gadolinium) |
| Renal trauma? | CT with contrast | Full organ assessment | Yes | YES (iodine) |
| Transplant function | Duplex ultrasound + nuclear imaging | Perfusion + function | No/Yes | NO |
COMPUTED TOMOGRAPHY
Non-Contrast CT (Best for Stones)
Indications: - Suspected urolithiasis - Renal size/contour - Hydronephrosis assessment - Post-procedural complications
Advantages: - 98% sensitivity, 96-100% specificity for stones - NO contrast risk - Fast; can detect non-calcified pathology (blood, perfusion changes) - Low radiation dose achievable with modern protocols
Disadvantages: - Cannot characterize renal masses (no enhancement pattern) - Cannot assess renal function - Radiation exposure
Contrast-Enhanced CT (for Masses and Vascular)
Phases of Enhancement: 1. Arterial phase (25-30 sec): Renal artery, hypervascular lesions 2. Nephrographic phase (80-100 sec): Peak parenchymal enhancement 3. Delayed phase (8-15 min): Collecting system, excretion
Clinical Uses: - Renal mass characterization (Bosniak classification for cysts) - CT angiography for RAS - Pyelonephritis, renal infarction - Transplant evaluation
Radiation Dose: 3-7 mSv (equivalent to 3 years background radiation)
CT Urography
Combines: - Non-contrast phase (baseline, stones, blood) - Nephrographic phase (mass detection) - Delayed excretory phase (collecting system, ureters, bladder)
Best for: Hematuria evaluation; detailed urinary tract assessment
RENAL ULTRASONOGRAPHY
Advantages: - NO radiation - Real-time imaging (can assess dynamics) - Bedside availability (POCUS) - Good for fluid assessment - Ideal in pregnancy, pediatrics
Disadvantages: - Operator-dependent (60-90% sensitivity range) - Reduced accuracy in obesity - Cannot assess contrast enhancement - Limited specificity for mass characterization
Key Measurements: - Renal length: Normal 9-13 cm (>9 cm preferred for biopsy) - Cortical thickness: Measured at level of hilum (normal >7-8 mm) - Collecting system dilatation: Anteroposterior pelvic diameter >10 mm suggests hydronephrosis (in context)
RENAL ARTERY DUPLEX ULTRASONOGRAPHY
For Renovascular Hypertension Screening:
Diagnostic Criteria: - Peak Systolic Velocity (PSV) >200 cm/s = significant stenosis (≥60%) - Renal-Aortic Ratio (RAR) >3.5 = additional evidence of stenosis - End-Diastolic Velocity >70 cm/s = hemodynamically significant
Sensitivity: 85-92% (in experienced hands) Specificity: 85-95%
Limitations: - Operator-dependent (learning curve: hundreds of exams) - Fails in 20-30% of obese patients - Cannot visualize accessory renal arteries reliably - Technical failure high in some institutions
NUCLEAR MEDICINE IMAGING
Diuretic Renogram (Lasix Renogram)
What It Does: Assesses function (not anatomy)
Protocol: 1. Give Tc-99m MAG3 radiopharmaceutical 2. Acquire images for 20 minutes (uptake phase) 3. Give furosemide at 20-minute mark (F+20 protocol) 4. Continue imaging 20 more minutes
Interpretation: - Time-to-Peak (TTP): When renal activity peaks (normal <3 min) - Half-Time (T1/2) post-diuretic: Time for activity to drop 50% (normal <10 min) - T1/2 >20 min = obstructive pattern - T1/2 10-20 min = equivocal (may need repeat/further imaging)
Best For: Distinguishing obstructive from non-obstructive hydronephrosis
DMSA Scintigraphy
What It Does: Images kidney cortex (high-resolution scarring assessment)
Uses: - Acute pyelonephritis (hypoperfusion areas) - Chronic scarring (from reflux or infection) - Differential renal function assessment - Pediatric pyelonephritis/reflux evaluation
Sensitivity: >95% for detecting scars >1 cm
SECTION 4: CONTRAST CONSIDERATIONS
Iodinated Contrast (Used in CT)
From “Contrast-Induced Nephropathy” to “Contrast-Associated Nephropathy”
Paradigm Shift: - Old term: Contrast-Induced Nephropathy (CIN) - implied direct causal relationship - New term: Contrast-Associated Nephropathy (CAN) - acknowledges other factors - Current: Contrast-Induced Acute Kidney Injury (CI-AKI) when probable causal relationship
Key Insight: Many post-contrast creatinine elevations are due to other factors (illness severity, dehydration, other medications), not the contrast itself.
Risk Stratification
Low Risk (Creatinine elevation <2%): - Normal renal function (eGFR >60) - No diabetes
Intermediate Risk (Creatinine elevation 5-10%): - eGFR 45-60 with diabetes OR eGFR 30-45 without diabetes - Age >75 - Heart failure
High Risk (Creatinine elevation 15-30%): - eGFR <30 - Diabetes + CKD - Multiple risk factors
Prevention: - IV hydration with normal saline (best evidence) - Sodium bicarbonate may help (controversial) - Metformin: Hold if eGFR <30; resume 48 hours post-contrast - NSAIDs: Hold 48 hours before and after - ACE-I/ARB: Can hold 24 hours before (optional)
Gadolinium-Based Contrast (Used in MRI)
The Nephrogenic Systemic Fibrosis (NSF) Risk
Group Classification (Risk of NSF):
| Group | Agents | NSF Risk | Recommendation |
|---|---|---|---|
| I (Highest) | Gadodiamide (Omniscan), Gadopentetate (Magnevist), Gadoversetamide (OptiMARK) | Higher risk | CONTRAINDICATED in eGFR <30 |
| II (Lowest) | Gadoteridol (ProHance), Gadoterate (Dotarem), Gadobutrol (Gadavist) | Minimal/NO NSF cases | Can use in eGFR <30; prefer these |
| III (Intermediate) | Others | Unknown | Use cautiously; prefer Group II |
Current Guidelines
NEW (2024): Group II GBCAs can be used even in advanced CKD (eGFR <30) or dialysis patients because: - No unconfounded NSF cases reported with Group II agents - Risk of not getting diagnostic imaging may outweigh minimal NSF risk - Use lowest effective dose
Practical Approach: - Check eGFR before MRI - If eGFR <30: Use Group II GBCA only (ProHance, Dotarem, Gadavist) - If eGFR >30: Any group acceptable (Group II still preferred) - Dialysis patients: Can receive Group II GBCA; no need to time dialysis
SECTION 5: CLINICAL INTERPRETATION
Reading a Renal CT Report
Standard Elements: 1. Kidney size: Length in cm (normal 9-13 cm) 2. Cortical thickness: Measured at hilum (normal >7 mm) 3. Enhancement pattern: Symmetric? Hypodense areas? 4. Collecting system: Dilated? Hydronephrosis present? 5. Vascular: Assess for stenosis, accessory arteries 6. Retroperitoneum: Free fluid? Mass? Fat stranding?
Red Flags: - Asymmetric renal atrophy → suggests chronic vascular disease or scarring - Stranding around kidney → infection, infarction, or hemorrhage - Enlarged kidney → acute obstruction, acute infection, or infiltration
SECTION 6: CLINICAL PEARLS
✓ Non-contrast CT is gold standard for suspected stones (98% sensitivity)
✓ CT angiography superior to duplex for diagnosing RAS (94-100% vs. 85-95%)
✓ eGFR accurate when stable but unreliable in AKI or extreme body habitus
✓ Cystatin C useful as complementary marker in borderline eGFR
✓ Ultrasound BEST for hydronephrosis screening, real-time assessment, pregnant patients
✓ Nuclear imaging best for FUNCTION (diuretic renogram for obstruction; DMSA for scars)
✓ Group II gadolinium is safe even in advanced CKD (no NSF cases reported)
✓ IV hydration prevents most contrast-related complications; more important than contrast selection
✓ Post-contrast creatinine elevation often has OTHER causes; not always “contrast-induced”
✓ Diuretic renogram (F+20 protocol) definitively distinguishes obstructive from non-obstructive hydronephrosis
PRACTICE QUESTIONS
Question 1: A 45-year-old male with CKD Stage 3b (eGFR 38) presents with hematuria. You need to evaluate for renal masses. Which imaging is BEST?
- Duplex ultrasound (no radiation)
- Non-contrast CT (no iodine contrast)
- Contrast-enhanced CT with iodine (multiplane imaging)
- MRI with gadolinium
Answer: C - For renal mass characterization, contrast-enhanced CT is superior because: - Iodine contrast allows assessment of enhancement (key for benign vs. malignant) - eGFR 38 = intermediate risk for contrast-related AKI (5-10%), but manageable with IV hydration - CT faster and more available than MRI - MRI would be alternative if contrast contraindicated, but is NOT first-line
Question 2: A 72-year-old woman with hypertension refractory to 3 agents has eGFR 42. You want to screen for renovascular hypertension. What is the BEST initial test?
- Renal artery duplex ultrasound
- Captopril renography
- CT angiography
- Start on alpha-blocker for “resistant HTN”
Answer: A - Duplex ultrasound is appropriate first-line because: - No radiation, no contrast - Sensitivity 85-92% (good enough for screening) - Low cost - Non-invasive - If positive → confirm with CTA before intervention - If negative + high suspicion → proceed to CTA - Duplex failure rate (20-30% in obese) means know your institution’s capability
Question 3: Labs show eGFR 65 by creatinine, but cystatin C suggests eGFR 52. What is the MOST likely explanation?
- Patient has early diabetic kidney disease
- Patient is a muscular bodybuilder with high creatinine production
- Cystatin C is unreliable; always trust creatinine
- Patient needs immediate dialysis referral
Answer: B - Discordance between creatinine-based and cystatin C eGFR suggests: - High muscle mass → high creatinine production → eGFR overestimated by creatinine - Cystatin C (muscle-independent) more accurate - Clinical decision: Trust cystatin C (52) rather than creatinine (65) - Implication: eGFR 52 = Stage 3b CKD; need closer monitoring/referral
In contrast, low muscle mass (elderly, cachetic) would show higher cystatin C-based eGFR, making creatinine-based eGFR the underestimate.
KEY TAKEAWAYS
✓ Lab panels vary by presentation (new vs. follow-up; suspected HTN vs. GN)
✓ eGFR useful for stable patients; unreliable in AKI, extreme body habitus
✓ Cystatin C complementary to creatinine; helps identify muscle mass issues
✓ CT best for anatomy (stones, masses, vasculature); ultrasound for real-time, radiation-free
✓ Nuclear imaging best for FUNCTION (diuretic renogram, DMSA)
✓ Iodine contrast safe in CKD with proper hydration; intermediate risk in Stage 3-4
✓ Gadolinium safe in advanced CKD if Group II agent used
✓ Ultrasound is best for pregnancy, pediatrics, real-time assessment
✓ Duplex ultrasound limited but appropriate for RAS screening in stable patients
✓ Diuretic renogram definitive for distinguishing obstructive vs. non-obstructive hydronephrosis
See Also
Clinical Content (01-Clinical-Medicine/Nephrology)
- Procedures and Diagnostics Hub
- CKD Hub - Full Clinical Reference
- AKI Hub - Full Clinical Reference
- Hypertension Management Hub
Butler-COM Resources
- Butler COM - Nephrology Deep Dive